SCAPIS 2 Cardio - Vibrometer Based Pulse Wave Analysis and CVD Risk Assessment
Launched by HJN SVERIGE AB/NEKO HEALTH · May 30, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The SCAPIS 2 Cardio trial is looking at a new technology that can help doctors measure how stiff the arteries are and how blood flows through them without needing to touch the patient. This study focuses on understanding heart health in people aged 58 to 72 years, particularly those with conditions like coronary artery disease, heart valve issues, or heart failure. The goal is to see how well this new device, called Cardio P4, works in a clinical setting and to determine its safety and accuracy in diagnosing heart-related problems.
To participate in this study, you need to be part of the larger SCAPIS 2 study at Danderyd Hospital in Stockholm and have already had an echocardiogram (a type of ultrasound for the heart). Unfortunately, if you can't give informed consent (which means you understand and agree to participate), you won't be eligible. If you join, you'll be helping researchers learn more about heart health while using a cutting-edge, non-invasive technology that could improve how we assess and treat heart conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects already included in the main / general SCAPIS 2 study at Danderyd Hospital in Stockholm, and of which has also participated in the echocardiography examination
- Exclusion Criteria:
- • Patients unable to provide an informed consent
About Hjn Sverige Ab/Neko Health
HJN Sverige AB, operating under the brand Neko Health, is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative technology and comprehensive health monitoring solutions. With a focus on harnessing cutting-edge artificial intelligence and data analytics, Neko Health aims to enhance patient outcomes and streamline clinical research processes. The organization is committed to fostering collaboration with medical professionals and research institutions to facilitate the development of groundbreaking therapies and improve overall health management. Through its rigorous approach to clinical trials, HJN Sverige AB seeks to contribute significantly to the future of personalized medicine and healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Trial Officials
Professor Jonas Spaak, MD, PhD
Principal Investigator
Karolinska Institute, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiovascular Medicine, Stockholm, Sweden
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported